The Anson Group is pleased to announce that Dr. Michael Langley is joining the company as a regulatory consultant after retiring from Eli Lilly & Co. Dr. Langley served many roles during his career with Lilly in both animal science and human pharmaceutical products, including director of regulatory affairs and clinical research. Dr. Langley led a number of successful regulatory engagements including both European and US regulatory submissions.
Indianapolis, IN (Vocus) January 30, 2010 -- The Anson Group announces today the addition of Dr. Michael Langley to its regulatory consulting practice. Dr. Langley is joining Anson Group after his recent retirement from Eli Lilly and Co. He has worked in the pharmaceutical industry since 1983, and has had a range of responsibilities and a broad variety of pharmaceutical products.
Early in his career, Dr. Langley worked for Elanco Animal Health, a Division of Eli Lilly, in a number of roles with increasing responsibilities including market research manager, project manager of animal health research, Director of European Regulatory and Clinical Affairs, and finally director of clinical research.
In 2002, Dr. Langley transitioned from animal health products to human pharmaceuticals at Eli Lilly. His experience includes establishing research priorities and timelines, successfully leading teams through US and EU marketing applications.
As the Director for Regulatory Affairs for Eli Lilly, Dr. Langley led project teams in label negotiations with the FDA, and several sNDA and sBLAapplica
Copyright©2010 Vocus, Inc.
All rights reserved